Cancer immunotherapy with enveloped self-amplifying mRNA CARG-2020 that modulates IL-12, IL-17 and PD-L1 pathways to prevent tumor recurrence
Chen J, Madina B, Ahmadi E, Yarovinsky T, Krady M, Meehan E, Wang I, Ye X, Pitmon E, Ma X, Almassian B, Nakaar V, Wang K. Cancer immunotherapy with enveloped self-amplifying mRNA CARG-2020 that modulates IL-12, IL-17 and PD-L1 pathways to prevent tumor recurrence. Acta Pharmaceutica Sinica B 2023, 14: 335-349. PMID: 38261838, PMCID: PMC10792965, DOI: 10.1016/j.apsb.2023.08.034.Peer-Reviewed Original ResearchCancer immunotherapyTumor recurrenceShort hairpin RNASurvival benefitIL-12Immune mechanismsLong-term survival benefitIL-17 receptor ACancer-promoting inflammationLarge established tumorsMultiple immune mechanismsPD-L1 pathwayT cell exhaustionDeath ligand 1Human cancer immunotherapySelf-amplifying mRNATumor-bearing miceVirus-like vesiclesMechanism of protectionCombined immunomodulationContralateral tumorsIL-17Established tumorsAbscopal effectImmunological memory